Thrombolex
Thrombolex innovates efficient endovascular catheters for precise, cost-effective treatment of A+VTE conditions since 2016.
- 11
- Company
- Kingston, NJ, USUnited States
Thrombolex innovates efficient endovascular catheters for precise, cost-effective treatment of A+VTE conditions since 2016.
thrombolex.comCrawled Oct 14, 2026
Disrupt and dissolve thrombus in a single on-the-table session. The THROMBOLEX device fissures the clot and delivers targeted lytic therapy into the thrombus rather than around it.
THROMBOLEX's privacy policy describes how it collects, uses, and shares personal data, and states that accessing its services constitutes acceptance of its practices and policies.
Thrombolex, Inc. presents interim results from its **RAPID-PE postmarket study**, covering the first **150 patients** enrolled. The study evaluates the company’s **Thrombolex device**, designed for mechanically channeled thrombolysis—a minimally invasive approach to dissolving blood clots in pulmonary embolism (PE). Early findings assess safety and efficacy in real-world clinical settings.
Oct 2026Endovascular TodayNews article
Thrombolex, Inc. raises **$50 million in Series A funding** to accelerate development of its **Pharmaco-Mechanical Lysis (PML) technology**, a novel approach to treating vascular blockages. The financing supports commercialization efforts, positioning the company to bring its solution to clinical and market applications. PML combines pharmacological and mechanical methods for targeted thrombus removal, addressing unmet needs in cardiovascular care.
Mar 2026PR.comNews article
Thrombolex enrolls the first two patients in the **RAPID-PE study**, testing its **Bashir endovascular catheter** for treating **acute pulmonary embolism (PE)**. The study evaluates the device’s safety and efficacy in clinical settings. This marks a key step in advancing minimally invasive treatments for PE patients.
Oct 2024Vascular Specialist OnlineNews article
Thrombolex secures FDA 510(k) clearance for its Bashir and Bashir S-B endovascular catheters, enabling treatment of acute pulmonary embolism. The devices expand the company’s portfolio of interventional solutions for critical vascular conditions. The clearance follows regulatory review under the FDA’s premarket notification pathway.
Apr 2023Cardiac Interventions TodayNews article